Headquartered in Lyon, France, Fabentech, established in 2009, is a leading biopharmaceutical company specializing in the development and production of emergency treatments to combat the most critical biological threats to public health. Their innovative Fabshield® platform is a safe and fully validated polyclonal antibody technology aiming to produce highly purified polyclonal antibodies capable of neutralizing viruses, toxins, and their potential variants, thereby halting disease progression.

Fabentech’s mission is to collaborate closely with governments and healthcare organizations, delivering timely and effective medical countermeasures to address bioterrorism agents and emerging infectious diseases during emergency situations. Their integrated R&D capabilities and proprietary manufacturing site enable them to rapidly deploy biodefense and pandemic preparedness solutions against diverse targets, ensuring reliable protection and treatment options in the face of escalating risks.

Fabentech’s produces broad-spectrum polyclonal antibodies that have proven to be effective against rapidly mutating pathogens or toxins with multiple variants.

FABENTECH has the largest pipeline of medical countermeasures in Europe for:
– Biodefense
– FBT-002, antitoxin program funded by the French Army against a plant-based toxin. Late-stage clinical phase with MA planned in 2025
– FBT-003, antitoxin program funded by the European Defense Fund. Status: PoC
– FBT-004, undisclosed antitoxin program.
– Antivirals
– Nipah virus infections, status: PoC
– Pan-sarbevovirus infections, status: discovery
– FabenFlu® a fully developed treatment against H5N1 avian flu with ODD status in Europe

–  Therapeutic areas: Infectious Diseases, Intoxications, Biodefense

–  Based in: Lyon (FRANCE)

–  Employees: 11 -50

–  Created in: 2009